Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole and octreotide combination therapy for treatment of Cushing's disease
2011-003264-77Phase 2
Key facts
- Status
- Active
- Start
- Sep 2011
- Countries
- 1
- Sponsor
- Erasmus MC
- Modality
- Peptides, Small Molecules
- Conditions
- Corticotropin adenoma (ACTHoma)
01
Overview
Phase 2, single-arm trial of ketoconazole, octreotide and cabergoline in Corticotropin adenoma (ACTHoma), sponsored by Erasmus MC. Primary endpoint: Urinary free cortisol. Started Sep 2011; status: active.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Ketoconazole + octreotide then octreotide monotherapy
Single-arm study in which all participants receive ketoconazole plus octreotide initially, followed by octreotide monotherapy for ongoing control of Cushing's disease.
03
Who it enrols
Adults with biochemically confirmed ACTH-dependent Cushing's syndrome originating from a pituitary adenoma (de novo, recurrent, or residual) are included; patients with impaired liver function are excluded.
04
Endpoints
Primary
Urinary free cortisol
Secondary
Cortisol diurnal rhythm (saliva and serum)
Bone metabolism parameters
Quality of life
Coagulation and fibrinolysis parameters
Beyond the preview
Go deeper on 2011-003264-77.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003264-77.